Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma

Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee

Producción científica: Article › revisión exhaustiva

35 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma'. En conjunto forman una huella única.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience